Hong Kong's new listing rules attract two more biotech startups

Hong Kong's new listing rules attract two more biotech startups

Ascletis Pharma listing ceremony in Hong Kong on Aug. Photographer: Anthony Kwan/Bloomberg

Two more Chinese drug developers are seeking initial public offerings in Hong Kong, adding to the growing wave of biotech firms taking advantage of the city’s new listing rules.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter